FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	_ OWNERSHIP

287								
Estimated average burden hours per response: 0.9								
0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     BRENNAN MURRAY			2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ ZIOP ]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner								
(Last) MEMOF	RIAL SLOA	irst) AN KETTERINC	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/13/2009									(give title		Other (s below)	·	
1275 YORK AVENUE			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	6. Individual or Joint/Group Filing (Check Applicable						
(Street)	ORK N	Y	10021											) Y	Form f	led by Mor		orting Perso I One Repo	
(City)	(S	tate)	(Zip)																
		Tak	le I - Non	-Deriva	ative	Se	curities	s Ac	quired,	Disp	osed o	f, or	Bene	ficially	/ Owned				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.					Securities Beneficially		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				,,
Common	Stock, \$.00	)1 par value													15,	000		D	
		•	Table II - I )						uired, D , option						Owned				
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution D if any (Month/Day/	Date, Transaction Code (Instr.			n of l		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				С	ode	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	0 N 0	umber					
Director Stock Option	\$4.31								(1)	1	2/22/2014	Comm Stoc \$.001 valu	k, par 1	5,029		15,029	9	D	
Stock Option (right to buy)	\$5.01								04/26/200	5 0	4/26/2016	Comr		5,000		15,000	)	D	
Stock Option (right to buy)	\$6.49								(2)	1	2/13/2016	Comm		5,000		15,000	)	D	
Stock Option (right to buy)	\$4.85								(3)	0	6/18/2017	Comm		5,000		15,00	0	D	
Stock Option (right to buy)	\$2.73								(4)	1	2/12/2017	Comm		0,000		20,000	)	D	
Stock Option (right to buy)	\$0.7	05/13/2009			A		15,000		(5)	0	5/13/2019	Comr		5,000	\$0	15,000	)	D	

## **Explanation of Responses:**

- 1. 7.515 shares vest on 12/22/05 and 7.514 shares vest on 12/22/06.
- 2. 5,000 shares vest on each of 12/13/07, 12/13/08 and 12/13/09.
- 3. 5,000 shares vest on each of 6/18/08, 6/18/09 and 6/18/10.
- 4. 6,667 shares vest on each of 12/12/08 and 12/12/09; 6,666 shares vest on 12/12/10.
- 5. 5,000 shares vest on each of 12/31/09, 6/30/10 and 12/31/10.

/s/ Murray Brennan

05/14/2009

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.